Blume K G, Forman S J
Blut. 1987 Jul;55(1):49-53. doi: 10.1007/BF00319642.
Five patients with hematologic malignancies who had relapsed between seven months and eight years after their primary bone marrow transplants were prepared with high dose busulfan/etoposide for second marrow transplantations from the same donors who had provided the marrow for the primary transplants. The preparatory regimen was well tolerated. All patients engrafted and entered complete remission. Two patients are alive and in continued remission two and ten months after second transplant. One patient died with acute respiratory failure after two months and two patients relapsed again eight and 17 months after second marrow transplantation. The combination busulfan/etoposide may prove to be a suitable preparatory regimen for second bone marrow transplant attempts in selected patients.
五例血液系统恶性肿瘤患者在首次骨髓移植后7个月至8年复发,接受了大剂量白消安/依托泊苷预处理,以便接受来自首次移植时提供骨髓的同一供者的第二次骨髓移植。预处理方案耐受性良好。所有患者均实现植入并进入完全缓解状态。两名患者在第二次移植后2个月和10个月存活且持续缓解。一名患者在两个月后死于急性呼吸衰竭,两名患者在第二次骨髓移植后8个月和17个月再次复发。白消安/依托泊苷联合方案可能被证明是适合特定患者进行第二次骨髓移植尝试的预处理方案。